The Magazine for Sleep Professionals
Monday, September 28, 2026
ResMed announced that it has entered into a definitive agreement to acquire Noctrix Health, a medical technology company focused on treating restless legs syndrome (RLS). The acquisition marks a strategic expansion of ResMed’s portfolio into adjacent neurological sleep disorders, reinforcing its mission to improve patient outcomes and quality of life. […]
Noctrix Health, Inc., the developer of the Nidra® Tonic Motor Activation (TOMAC) therapy for Restless Legs Syndrome (RLS), announced a significant expansion of private financing to accelerate its U.S. commercial launch. The company also announced several key leadership appointments to strengthen its commercial and scientific teams. Financing Update Noctrix Health […]
Noctrix Health, Inc. announced that it has closed a $40M Series C financing round led by Sectoral Asset Management with participation from other new investors Angelini Ventures, ResMed, and Asahi Kasei Corporation, with strong support from insiders, including OrbiMed and Treo Ventures. This infusion of capital will propel the advancement […]
Noctrix Health, Inc. announced a double feature in the renowned peer-reviewed journal, Sleep, showcasing the outcomes of two major clinical trials that assessed TOMAC therapy for the treatment of restless legs syndrome (RLS). The two papers feature the results from the RESTFUL study (NCT04874155), a multi-center, randomized, sham-controlled clinical trial, and a subsequent […]
Noctrix Health, Inc. announced that the first patient has been enrolled in a multi-center, randomized controlled clinical trial. The RESTFUL Study (ClinicalTrials.gov Identifier: NCT04874155) is a first of its kind two-phase, randomized, double-blind, sham-controlled clinical trial to evaluate the Company’s proprietary wearable NTX100 Neuromodulation System in patients with moderate-severe primary RLS […]
